Effect of angiotensin-converting enzyme or vasopeptidase inhibition on ventricular size and function in patients with heart failure: The Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) echocardiographic study

American Heart Journal

Volumn 150, Issue 2, 2005, Pages 257-262

  Solomon, Scott D ^a,i   Skali, Hicham ^a   Bourgoun, Mikhail ^a   Fang, James ^a   Ghali, Jalal K ^b   Martelet, Michel ^c   Wojciechowski, Dariusz ^d   Ansmite, Baiba ^e   Skards, Janis ^e   Laks, Toivo ^f   Henry, David ^g   Packer, Milton ^h   Pfeffer, Marc A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Cardiac Centers of Louisiana   (United States)

^c Centre Hospitalier de Langres   (France)

^d Hospital Linezers ^*  (Poland)

^e Hospital Linezers   (Latvia)

^f Central Hospital   (Estonia)

^g BRISTOL MYERS SQUIBB   (United States)

^h New York Presbyterian Hospital Columbia University Medical Center   (United States)

ⁱ BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; OMAPATRILAT; VASOPEPTIDASE INHIBITOR;

ADULT; AGED; ARTICLE; CLINICAL EXAMINATION; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DIASTOLE; ECHOCARDIOGRAPHY; ENZYME INHIBITION; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE SIZE; HEART LEFT VENTRICLE VOLUME; HEART VENTRICLE REMODELING; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLE; TREATMENT OUTCOME;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ATRIAL NATRIURETIC FACTOR; COHORT STUDIES; ENALAPRIL; FEMALE; HEART FAILURE, CONGESTIVE; HEART VENTRICLES; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MALE; MIDDLE AGED; NEPRILYSIN; ORGAN SIZE; PROPORTIONAL HAZARDS MODELS; PROTEASE INHIBITORS; PYRIDINES; REPRODUCIBILITY OF RESULTS; STROKE VOLUME; SURVIVAL ANALYSIS; THIAZEPINES; TREATMENT OUTCOME; VENTRICULAR REMODELING;

EID: 23644443397     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ahj.2004.09.056     Document Type: Article

References (24)

1. M.A. Pfeffer, E. Braunwald, and L.A. Moye Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial N Engl J Med 327 1992 669 677
2. M. St John Sutton, M.A. Pfeffer, and T. Plappert Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril Circulation 89 1994 68 75
3. The SOLVD investigators Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure N Engl J Med 325 1991 293 302
4. M.A. Konstam, M.F. Rousseau, and M.W. Kronenberg Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators Circulation 86 1992 431 438
5. H.G. Pouleur, M.A. Konstam, and J.E. Udelson Changes in ventricular volume, wall thickness and wall stress during progression of left ventricular dysfunction. The SOLVD Investigators J Am Coll Cardiol 22 4, Suppl. A 1993 43A 48A
6. J.A. Robl, C.Q. Sun, and J. Stevenson Dual metalloprotease inhibitors: Mercaptoacetyl-based fused heterocyclic dipeptide mimetics as inhibitors of angiotensin-converting enzyme and neutral endopeptidase J Med Chem 40 1997 1570 1577
7. N.C. Trippodo, J.A. Robl, and M.M. Asaad Effects of omapatrilat in low, normal, and high renin experimental hypertension Am J Hypertens 11 1998 363 372
8. C. Massien, M. Azizi, and T.T. Guyene Pharmacodynamic effects of dual neutral endopeptidase-angiotensin-converting enzyme inhibition versus angiotensin-converting enzyme inhibition in humans Clin Pharmacol Ther 65 1999 448 459
9. N. Lapointe, C. Blais Jr., and A. Adam Comparison of the effects of an angiotensin-converting enzyme inhibitor and a vasopeptidase inhibitor after myocardial infarction in the rat J Am Coll Cardiol 39 2002 1692 1698
10. J.L. Rouleau, M.A. Pfeffer, and D.J. Stewart Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial Lancet 356 2000 615 620
11. M. Packer, R.M. Califf, and M.A. Konstam Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) Circulation 106 2002 920 926
12. M. St John Sutton, M.A. Pfeffer, and T. Plappert Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril Circulation 89 1994 68 75
13. M.A. Pfeffer, S.C. Greaves, and J.M. Arnold Early versus delayed angiotensin-converting enzyme inhibition therapy in acute myocardial infarction. The healing and early afterload reducing therapy trial Circulation 95 1997 2643 2651
14. T.B. Levine, A.B. Levine, and S.J. Keteyian Reverse remodeling in heart failure with intensification of vasodilator therapy Clin Cardiol 20 1997 697 702
15. B. Mettauer, J.L. Rouleau, and D. Bichet Differential long-term intrarenal and neurohormonal effects of captopril and prazosin in patients with chronic congestive heart failure: Importance of initial plasma renin activity Circulation 73 1986 492 502
16. A. Goussev, V.G. Sharov, and H. Shimoyama Effects of ACE inhibition on cardiomyocyte apoptosis in dogs with heart failure Am J Physiol 275 1998 H626 H631
17. M. Pahor, R. Bernabei, and A. Sgadari Enalapril prevents cardiac fibrosis and arrhythmias in hypertensive rats Hypertension 18 1991 148 157
18. W.W. Brooks, O.H. Bing, and K.G. Robinson Effect of angiotensin- converting enzyme inhibition on myocardial fibrosis and function in hypertrophied and failing myocardium from the spontaneously hypertensive rat Circulation 96 1997 4002 4010
19. J.C. Burnett Jr. Vasopeptidase inhibition: a new concept in blood pressure management J Hypertens Suppl 17 1999 S37 S43
20. N.C. Trippodo, M. Fox, and T.M. Monticello Vasopeptidase inhibition with omapatrilat improves cardiac geometry and survival in cardiomyopathic hamsters more than does ACE inhibition with captopril J Cardiovasc Pharmacol 34 1999 782 790
21. N. Lapointe, Q.T. Nguyen, and J.F. Desjardins Effects of pre-, peri-, and postmyocardial infarction treatment with omapatrilat in rats: survival, arrhythmias, ventricular function, and remodeling Am J Physiol Heart Circ Physiol 285 2003 H398 H405 [Electronic publication 2003 Mar 27]
22. T. Backlund, E. Palojoki, and A. Saraste Effect of vasopeptidase inhibitor omapatrilat on cardiomyocyte apoptosis and ventricular remodeling in rat myocardial infarction Cardiovasc Res 57 2003 727 737
23. D.R. McClean, H. Ikram, and A.H. Garlick The clinical, cardiac, renal, arterial and neurohormonal effects of omapatrilat, a vasopeptidase inhibitor, in patients with chronic heart failure J Am Coll Cardiol 36 2000 479 486
24. J.E. Udelson, and M.A. Konstam Relation between left ventricular remodeling and clinical outcomes in heart failure patients with left ventricular systolic dysfunction J Card Fail 8 6 Suppl 2002 S465 S471